Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05862805 · ClinicalTrials.gov registry record · Phase 1
PAI-1, tPA, TFPI and HEECs in Uterine Hemostasis
A Phase 1 study of Menstrual Bleeding, Heavy, sponsored by Oregon Health and Science University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
- 1
- Study location
NCT05862805: Recruiting Phase 1 study of Menstrual Bleeding, Heavy, sponsored by Oregon Health and Science University.
NCT05862805 is a Phase 1 study of Menstrual Bleeding, Heavy that is actively recruiting participants, run by Oregon Health and Science University. The registered enrollment target is 70 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (17% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05862805, a Phase 1 study of Menstrual Bleeding, Heavy, is actively recruiting participants, sponsored by Oregon Health and Science University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to learn more about the role of blood clotting factor proteins and cells in menstrual (period) bleeding. The investigators are hoping to identify differences in these proteins and cells in the menstrual blood of individuals with heavy periods compared to menstruating individuals who do not have heavy periods.
Conditions Studied
Interventions
- PROCEDURE Sample Collection and Endometrial Biopsy
Study Locations (1)
Oregon
- OHSU - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2023-07-12 |
| Est. Completion | 2026-07 |
| Phase | Phase 1 |
What NCT05862805 shows while recruiting
NCT05862805 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (17% higher).
The record links to 1 condition, with Menstrual Bleeding, Heavy appearing as the primary indexed condition, and to 1 intervention - of which Sample Collection and Endometrial Biopsy is the first listed.
NCT05862805 reports a single indexed study location in Oregon.
Frequently Asked Questions
What is clinical trial NCT05862805 about?
NCT05862805 is a clinical study titled "PAI-1, tPA, TFPI and HEECs in Uterine Hemostasis". The purpose of the study is to learn more about the role of blood clotting factor proteins and cells in menstrual (period) bleeding. The investigators are hoping to identify differences in these proteins and cells in the menstrual blood of individuals with heavy periods compared to menstruating indi...
What is the current status of trial NCT05862805?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2023-07-12. Estimated completion is 2026-07.
What conditions does trial NCT05862805 study?
This clinical trial studies the following conditions: Menstrual Bleeding, Heavy.
What interventions are being tested in trial NCT05862805?
The interventions under investigation include: Sample Collection and Endometrial Biopsy (PROCEDURE).
Who is sponsoring clinical trial NCT05862805?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05862805 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Menstrual Bleeding, Heavy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05862805's enrollment target sits among peer trials
70 749th of 2000 higher than 1,227 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI